H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on PDS Biotechnology (PDSB – Research Report) today and set a price target of $21.00.
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily centered around the promising results of PDS Biotechnology’s Versamune platform. The recent publication in Clinical Cancer Research highlighted the efficacy of Versamune HPV in clearing circulating tumor DNA (ctDNA) in patients with locally advanced cervical cancer. The IMMUNOCERV Phase 2 trial results demonstrated that patients receiving Versamune HPV in combination with chemoradiotherapy showed a faster clearance of HPV16-positive cancer cells from the bloodstream compared to those receiving chemoradiotherapy alone.
Moreover, the study indicated a significant improvement in two-year recurrence-free survival rates for patients with undetectable HPV16 ctDNA at 3-4 months. These findings not only reinforce the potential of Versamune HPV in treating cervical cancer but also suggest broader applications for other HPV16-positive cancers, such as head and neck squamous cell carcinoma. The planned VERSATILE-003 Phase 3 trial further supports the optimistic outlook for PDS Biotechnology, contributing to Pantginis’s Buy rating.
Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Viking Therapeutics, and Esperion. According to TipRanks, Pantginis has an average return of -4.2% and a 29.78% success rate on recommended stocks.